Cardiovascular disease (CVD) can affect up to two-thirds of patients with chronic kidney disease (CKD) and is the leading cause of death among them.1 Given the strong interrelation between the progression of CKD and the risk of CVD, the currently recommended standard of practice is the holistic management of traditional risk factors, including hypertension, diabetes, and dyslipidemia.2 However, despite recent advances in risk reduction, including the use of sodium/glucose cotransporter 2 (SGLT2) inhibitors and nonsteroidal mineralocorticoid receptor antagonists,3 the risk of CVD is still high, and the decline in the CVD mortality rates observed in the general population has not been mirrored in patients with CKD.